FDAnews Drug Daily Bulletin

BIOMERIEUX SELLS ITS HEMOSTASIS LINE OF BUSINESS

May 26, 2006
A A

bioMerieux, a global leader in the field of in vitro diagnostics, today announced that it has signed an agreement to sell its hemostasis range of products to Trinity Biotech plc. The company's hemostasis line includes the MDA, MTX and Thrombolyzer platforms, as well as a comprehensive menu of reagents to analyze blood clotting parameters.
PR Newswire